Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391686 | 0.87 | HSD17B10 (0.48) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL29740027 | 0.87 | HSD17B10 (0.48) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL1636077 | 0.86 | TDP1 (0.60) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL14411817 | 0.85 | TDP1 (0.54) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL574038 | 0.83 | TDP1 (0.50) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL29888274 | 0.83 | TDP1 (0.50) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL3192674 | 0.82 | TSHR (0.65) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL20942954 | 0.82 | TDP1 (0.47) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL18589140 | 0.82 | ALDH1A1 (0.49) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL18311461 | 0.81 | TDP1 (0.56) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340556-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2011-05-05 | — | — | US | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | TSHR 4209/4885SMN1; SMN2 3532/4885TDP1 1839/4885 |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, PEPD, ABCB11 | TSHR 4680/4885SMN1; SMN2 4436/4885TDP1 4832/4885 |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | TSHR 4061/4885SMN1; SMN2 22/4885TDP1 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.